Eli Lilly and Company
LLY · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $5,582,500 | $5,660,500 | $2,759,300 | $4,409,800 |
| Dep. & Amort. | $470,000 | $478,500 | $462,800 | $484,800 |
| Deferred Tax | $501,400 | -$1,068,700 | -$391,600 | -$966,700 |
| Stock-Based Comp. | $151,100 | $185,100 | $153,700 | $141,900 |
| Change in WC | $5,627,100 | -$2,262,900 | -$3,364,200 | -$2,224,900 |
| Other Non-Cash | -$3,496,200 | $94,400 | $2,045,600 | $628,900 |
| Operating Cash Flow | $8,835,900 | $3,086,900 | $1,665,600 | $2,473,800 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,087,700 | -$1,697,100 | -$1,509,500 | -$1,496,000 |
| Net Acquisitions | -$549,400 | $0 | $0 | $0 |
| Inv. Purchases | -$150,100 | -$171,200 | -$196,700 | -$182,100 |
| Inv. Sales/Matur. | $556,100 | $204,300 | $71,600 | $97,200 |
| Other Inv. Act. | -$751,500 | -$170,900 | -$1,717,700 | -$339,600 |
| Investing Cash Flow | -$2,982,600 | -$1,834,900 | -$3,352,300 | -$1,920,500 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $2,614,500 | $824,700 | $4,612,300 | $3,042,300 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$708,100 | -$692,200 | -$1,200,000 | -$2,053,900 |
| Dividends Paid | -$1,345,200 | -$1,347,000 | -$1,346,300 | -$1,168,300 |
| Other Fin. Act. | -$30,200 | -$30,400 | -$686,300 | -$45,500 |
| Financing Cash Flow | $531,000 | -$1,244,900 | $1,379,700 | -$225,400 |
| Forex Effect | $31,700 | $275,500 | $131,900 | -$428,500 |
| Net Chg. in Cash | $6,416,000 | $282,600 | -$175,100 | -$100,600 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $3,375,900 | $3,093,300 | $3,268,400 | $3,369,000 |
| End Cash | $9,791,900 | $3,375,900 | $3,093,300 | $3,268,400 |
| Free Cash Flow | $8,612,000 | $1,283,000 | -$1,600,900 | $726,600 |